Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Two-year clinical outcomes of patients with the second-generation cobalt-chromium sirolimus-eluting stents from the real-world FOCUS registry.

Zhang F, Ge J, Qian J, Ge L, Zhou J; FOCUS registry investigators.

Int J Cardiol. 2013 Jul 1;166(3):750-2. doi: 10.1016/j.ijcard.2012.09.172. Epub 2012 Oct 10. No abstract available.

PMID:
23063137
2.

Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent.

Xu B, Zhang Q, Yang YJ, Qiao SB, Zhang RY, Zhang JS, Hu J, Qin XW, Hong T, Li JP, Chen JL, Huo Y, Gao RL, Shen WF.

Chin Med J (Engl). 2008 Mar 20;121(6):492-7.

PMID:
18364131
3.

Six-month clinical outcomes of Firebird 2TM sirolimus-eluting stent implantation in real-world patients with coronary artery diseases.

Ge JB, Zhang F, Qian JY, Ge L, Liu XB, Zhou J.

Chin Med J (Engl). 2011 Mar;124(6):831-5.

PMID:
21518588
4.

Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry.

Zhang F, Ge J, Qian J, Ge L, Zhou J; FOCUS registry investigators.

EuroIntervention. 2012 Dec 20;8(8):896-903. doi: 10.4244/EIJV8I8A138.

5.

Time dependency of outcomes for drug-eluting vs bare-metal stents.

Leung AA, Southern DA, Galbraith PD, Knudtson ML, Philpott AC, Ghali WA; APPROACH Investigators.

Can J Cardiol. 2013 Dec;29(12):1616-22. doi: 10.1016/j.cjca.2013.09.003.

PMID:
24267804
6.

Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry.

Meredith I, Rothman M, Erglis A, Parikh K, Lotan C; E-Five Investigators.

Catheter Cardiovasc Interv. 2011 Jun 1;77(7):993-1000. doi: 10.1002/ccd.22803. Epub 2010 Dec 3.

PMID:
20853351
7.

Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.

Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, Kang HJ, Koo BK, Cho J, Gwon HC, Lee SY, Chae IH, Youn TJ, Chae JK, Han KR, Yu CW, Kim HS.

J Am Coll Cardiol. 2013 Feb 5;61(5):536-44. doi: 10.1016/j.jacc.2012.11.015. Epub 2012 Dec 26.

8.

Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Kuck KH; DES.DE Study Group.

Am J Cardiol. 2009 Nov 15;104(10):1362-9. doi: 10.1016/j.amjcard.2009.06.058. Epub 2009 Sep 26.

PMID:
19892051
9.

Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study.

Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Her SH, Hur SH, Park JS, Kim MK, Choi YS, Kim HS, Cho JH, Lee SG, Park YW, Jeong MH, Lee BK, Lee NH, Lim DS, Yoon J, Seung KB, Shin WY, Rha SW, Kim KS, Tahk SJ, Park BE, Ahn T, Yang JY, Jeong YS, Rhew JH, Park SJ; IRIS-DES Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):365-71. doi: 10.1161/CIRCINTERVENTIONS.111.966549. Epub 2012 Jun 12.

10.

A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.

Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators.

J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8. doi: 10.1016/j.jacc.2011.02.016. Epub 2011 Apr 4.

11.

Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).

Hanna NN, Gaglia MA Jr, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R.

Am J Cardiol. 2010 Aug 15;106(4):504-10. doi: 10.1016/j.amjcard.2010.04.001.

PMID:
20691308
12.

Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.

Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S.

Circulation. 2012 Mar 6;125(9):1110-21. doi: 10.1161/CIRCULATIONAHA.111.058560. Epub 2012 Feb 1.

13.

Meta-analysis of everolimus-eluting stent as compared to sirolimus-eluting stent in patients undergoing percutaneous coronary interventions: an update.

Chen H, Liu K.

Int J Cardiol. 2011 Jul 1;150(1):101-3. doi: 10.1016/j.ijcard.2011.03.041. Epub 2011 Apr 15. No abstract available.

PMID:
21497406
14.

Everolimus- versus first generation drug-eluting stents: the never-ending story of searching for a winner in the "limus family".

Cassese S, Piccolo R, Galasso G, Piscione F.

Int J Cardiol. 2011 Jul 15;150(2):212. doi: 10.1016/j.ijcard.2011.05.008. Epub 2011 Jun 2. No abstract available.

PMID:
21640408
15.

Six-year clinical outcomes of first-generation drug-eluting stents: a propensity-matched analysis.

Tarantini G, Barioli A, Facchin M, Frigo AC, Napodano M, Buja P, D'Amico G, Iliceto S, Isabella G.

Coron Artery Dis. 2013 Aug;24(5):440-8. doi: 10.1097/MCA.0b013e328362b2ab.

PMID:
23695366
16.

Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.

Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K; j-Cypher Registry Investigators.

Circulation. 2012 Jan 31;125(4):584-91. doi: 10.1161/CIRCULATIONAHA.111.046599. Epub 2011 Dec 27.

17.

Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.

Cassese S, Piccolo R, Galasso G, De Rosa R, Piscione F.

Int J Cardiol. 2011 Jul 1;150(1):84-9. doi: 10.1016/j.ijcard.2011.01.015. Epub 2011 Feb 18.

PMID:
21315461
19.

Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.

Abdel-Wahab M, Nienaber CA, Mostafa AE, Sabin G, Tebbe U, Hochadel M, Senges J, Akin I, Kuck KH, Hamm C, Richardt G; German Drug-Eluting Stent (DES.DE) registry.

EuroIntervention. 2011 Jun;7(2):201-8. doi: 10.4244/EIJV7I2A34.

20.

Comparison of five-year outcome of octogenarians undergoing percutaneous coronary intervention with drug-eluting versus bare-metal stents (from the RESEARCH and T-SEARCH Registries).

Cheng JM, Onuma Y, Piazza N, Nuis RJ, Van Domburg RT, Serruys PW; Interventional Cardiologists of Thoraxcenter (2000-2009).

Am J Cardiol. 2010 Nov 15;106(10):1376-81. doi: 10.1016/j.amjcard.2010.07.007. Epub 2010 Oct 1.

PMID:
21059424

Supplemental Content

Support Center